Racemates versus enantiomerically pure drugs: putting high-performance liquid chromatography to work in the selection...

Area of Science:

• Pharmaceutical Chemistry
• Medicinal Chemistry
• Drug Development

Background:

• Growing scrutiny of multi-drug pharmaceutical preparations highlights the importance of stereoisomeric composition.
• Increasingly stringent drug purity requirements necessitate a re-evaluation of racemic mixtures.
• The stereoisomeric composition of drugs is a critical factor in development, regulatory approval, and marketing.

Purpose of the Study:

• To explore the complexities of stereoisomerism in drug development.
• To evaluate whether racemic mixtures should be considered inherently impure.
• To discuss the balance between risk-benefit and cost-benefit factors in deciding on enantiomerically pure drugs.

Main Methods:

• Comparative evaluation of enantiomer activities, toxicities, and pharmacokinetics.
• Risk-benefit and cost-benefit analyses for drug safety.
• Discussion of analytical methods for enantioselective separations, particularly high-performance liquid chromatography (HPLC).

Main Results:

• The decision on whether to use racemic mixtures or single enantiomers is complex, requiring careful evaluation of multiple factors.
• Excessive development costs and regulatory burdens can be mitigated by considering drug potency and isomer toxicity.
• Appropriate analytical methods are essential throughout preclinical and clinical development.

Conclusions:

• Stereochemistry plays a pivotal role in modern drug development.
• High-performance liquid chromatography (HPLC) is a key tool for enantioselective separation and analysis.
• Balancing safety, efficacy, and economic factors is crucial for regulatory approval and marketing of chiral drugs.